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Original Article 
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Abstract: Neuroimaging is a central part of diagnostic work-up of patients with suspected neurodegenerative di-
sease. FDG-PET can reveal pathological changes earlier and more reliably than morphological imaging. Diagnostic 
accuracy can be improved by constructing 3D SSP Z-score maps, showing patterns of significant deficits. During 
FDG-PET, the subject receives a moderate but not insignificant dose of ionizing radiation, and a dose reduction with 
retained image quality is desirable. With lower dose, repeated examinations can become a useful tool for monitor-
ing disease progress and potential effects of disease-modifying interventions. The aim of this study was to evaluate 
Z-maps created from low-dose and normal-dose FDG-PET of the brain, with quantitative and qualitative methods. 
Nine patients with neurodegenerative disorders were prospectively enrolled and nine age-matched controls were 
recruited through advertising. All subjects (n=18) underwent two FDG-PET scans on separate occasions; a routine 
and a low-dose scan. The routine dosage of FDG was 3 MBq/kg, and low dosage was 0.75 MBq/kg. 3D-SSP images 
showing Z-scores of < -1.96 were created from 10-minute summations. The study was comprised of a quantitative 
part comparing the Z-scores, and a qualitative part where experienced nuclear medicine specialists visually as-
sessed the images. Regarding the quantitative part, Bland-Altman analysis showed a slight constant bias (0.206). 
Regarding qualitative discrimination between patients and controls, the performance between normal- and low-
dose were equal, both showing 72% sensitivity, 83% specificity and 78% accuracy. In this study, visual assessment 
of 3D-SSP Z-score maps from low-dose FDG-PET provided diagnostic information highly comparable to normal-dose, 
with minor quantitative discrepancies.
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Introduction
In 2015, there were 46.8 million patients with 
dementia disorders worldwide and according to 
current prognoses there will be 131.5 million by 
2050 [1]. If or when disease-modifying drugs 
become available, establishing an early diagno-
sis will be of paramount importance. During 
recent years, neuroimaging has become a cen-
tral part in the diagnostic work-up of patients 
with suspected neurodegenerative disease, to 
exclude treatable causes and to support clini-
cal findings [2]. Morphological changes such as 
atrophy are evident late in the disease pro-
gress, and physiological markers stand a better 
chance for establishing an early diagnosis [3]. 
PET examination using 18F-Fluorodeoxyglucose 
(FDG) reflects transport of glucose into cells, 
and energy-demanding synaptic activity leads 
to increased regional glucose uptake. Tracer 
uptake is mainly driven by basal neuronal activ-
ity [3], and regions of reduced activity are visu-
alized as areas of “hypometabolism”. Several 
overviews on typical deficit patterns that can be 
used to discriminate neurodegenerative dis-
eases have been published [4, 5]. FDG-PET can 
reveal pathological changes earlier and more 
reliably than morphological imaging and even 
neuropsychological testing [3]. 
Reliable assessment of FDG-PET images 
requires a high level of expertise and might be 
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challenging in early stages of disease. Since 
its introduction in the 1990-s [6], the use of 
automated 3D-stereotactic spatial normaliza-
tion maps (3D-SSP maps) has been an increas-
ingly important part of clinical evaluation. The 
3D-SSP method defines a large number of 
points on a spatially normalized brain surface 
and compares the data from the individual with 
a database of healthy controls. The result can 
be used to highlight cortical areas with statisti-
cally significant deficits. These deficit maps, 
referred to as Z-score maps due to the underly-
ing statistical calculations (or simply Z-maps), 
optimizes the pattern recognition in the reader 
and facilitate differential diagnosis. FDG-based 
Z-maps have been shown to improve the accu-
racy of diagnosing neurodegenerative disease 
[3, 7], especially for novice readers [8]. 
There are several commercially available soft-
ware packages with a 3D-SSP function, e.g. 
HybridViewer BRASS (Hermes medical solu-
tions), CortexID (GE Healthcare), Neurostat 
3D-SSP (University of Michigan, USA), and SPM 
(Wellcome Dept. London, UK). 3D-SSP maps 
are commonly used clinically, both for FDG and 
amyloid imaging, and method optimization is 
ongoing [9].
During FDG-PET, the subject receives a moder-
ate but not insignificant dose of ionizing radia-
tion [10]. For many patients, this is of negligible 
importance due to old age and concurrent 
disease, but for younger patients and for the 
prospect of repeated examinations, a dose 
reduction with retained image quality is desira-
ble. With lower dose, repeated examinations 
become a useful tool for monitoring disease 
progress and potential effects of a disease-
modifying intervention. For research purposes, 
the possibility to perform low-dose FDG-PET 
examinations opens up for facilitated inclusion 
of healthy controls, even for repeated examina-
tions. A normal-dose scan with shorter acquisi-
tion time is a close but not perfect approxima-
tion of a true low-dose scan. An important dif-
ference is a higher count rate, and consequent-
ly higher random coincidence rates and dead 
time during a shortened normal-dose scan, 
which would negatively affect image quality 
compared to a true low-dose scan. 
It was recently shown that true low-dose FDG-
PET provided highly similar regional SUV ratios 
compared to normal-dose without increasing 
scan time [11]. However, due to the statistical 
properties of the Z-score method, and limita-
tions such as database size in the software 
tools, it remains to be shown that reliable Z- 
maps can be created from low-dose FDG-PET. 
In clinical routine, maps showing Z-scores fil-
tered at -1.96 standard deviations are com-
monly used to show areas of significant deficits. 
This is considered a robust diagnostic method 
and the current study is based on assessing 
such maps. The aim of this study was to evalu-
ate the reliability of 3D-SSP Z-score maps cre-
ated from low-dose FDG-PET of the brain, com-




Nine patients (mean age 71.7, 78% males) who 
had received a clinical probability diagnosis of 
neurodegenerative dementia disease were pro-
spectively enrolled from the memory clinic at 
Table 1. Included subjects
Subject Diagnosis Gender Age 1st dose 2nd dose
1 Control M 70 314 87
2 Control M 69 280 72
3 Control M 78 220 56
4 Control M 84 298 84
5 Control M 64 261 63
6 Control F 70 215 58
7 Control F 68 240 54
8 Control F 77 190 45
9 Control F 78 155 35
10 SD M 82 264 62
11 bvFTD M 76 244 49
12 bvFTD M 56 248 66
13 AD M 69 227 54
14 bvFTD F 59 161 35
15 LBD M 74 207 57
16 CBD F 84 164 49
17 LBD M 71 239 47
18 bvFTD M 74 251 63
Diagnosis (SD = semantic dementia, bvFTD = behavioural 
variant frontotemporal dementia, AD = Alzheimer’s disease, 
LBD = Lewy body dementia, CBD = corticobasal degenera-
tion). 1st dose represents the normal-dose scan, in MBq. 
2nd dose represents the low-dose, also in MBq. A large part 
of this material was also included in a previously published 
article [11].
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the geriatric department. Five patients had 
been diagnosed with frontotemporal dementia 
(behavioural variant (bvFTD), n=4; semantic 
dementia (SD), n=1, collectively referenced as 
FTD), two patients with Lewy body dementia 
(LBD), and one each with Alzheimer’s disease 
(AD) and corticobasal degeneration (CBD), res- 
pectively. The diagnoses imply that all patients 
had neurodegenerative diseases with assumed 
or previously proven regional hypometabolism, 
identifiable on FDG-PET. 
Nine cognitively normal controls (mean age 
71.9, 57% males) were recruited through 
advertising. A structured interview, physical 
examination, and neuropsychological tests 
(MMSE, TMTa, 7-min screening) were perform- 
ed to exclude pathology and confirm normal 
cognition. All subjects (n=18) underwent PET/
CT twice, as described below. Information 
about the included subjects is summarized 
in Table 1. The subjects and FDG protocol 
described here are previously published in 
greater detail [11, 12].
sition mode. Images were reconstructed us- 
ing ordered-subsets expectation maximization 
(OSEM; 2 iterations, 21 subsets) with a 2.14 
mm FWHM post-filter, applying appropriate cor-
rections including attenuation correction based 
on a low-dose CT scan (effective dose 0.07 
mSv). Voxel size of the resulting images was 2 × 
2 × 3.7. The average time interval between the 
two examinations was 31 days.
Image post-processing
3D-SSP images showing Z-scores of < -1.96 
(henceforth called Z-maps) were created from 
10-minute summations (35-45 min) of both 
ND and LD scans, using batch analysis in 
HybridViewer BRASS 2.6A.10, Hermes Medical 
Solutions. Regional Z-scores from 47 regions 
of interest were generated by the automated 
atlas function inherent of the BRASS software, 
using the cerebellum as reference region. The 
study was comprised of a quantitative part 
comparing the Z-scores, and a qualitative part 
where experienced readers visually assessed 
the 3D-SSP Z-maps, as described below.
Figure 1. Comparisons of Z-maps from a routine scan with normal dose, and 
low-dose scan. The figure contains sample images from all included patients 
in the study (not the controls). The numbers to the left of the images repre-
sent the subject numbers. Subject number 16 had the largest difference be-
tween normal and low dose according to the assessments described below.
The study was approved by 
the Regional Board of Medical 
Ethics, and all subjects pro-
vided written informed con-
sent. For most patients, a pre-
sent family member co-signed 
the consent. 
FDG-PET protocol
All scans were acquired 35- 
45 min after tracer injection. 
A routine scan (normal-dose, 
ND) with an injected dose of 
3 MBq/kg FDG was perform- 
ed first. The average adminis-
tered activity was 236 MBq 
(effective dose from FDG 4.5 
mSv). The second scan, per-
formed on a separate occa-
sion, was a low-dose (LD) scan 
using 25% of the normal dose, 
i.e. 0.75 MBq/kg (mean admi- 
nistered activity 57 MBq, eff- 
ective dose from FDG 1.1 
mSv. 
All subjects were scanned 
on a Discovery ST (GE Health- 
care, Waukesha, WI, USA) 
PET/CT scanner in 3D acqui- 
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Readers
Two nuclear medicine specialists with vast 
clinical experience of FDG-PET dementia diag-
nostics were readers in this study (TD, VI). The 
images were presented in a random, blinded 
fashion. The reading was divided into two ses-
sions, performed on separate occasions.
Session one
In the first session of visual assessment, the 
readers viewed randomized Z-maps from each 
subject individually, without knowing if the 
images were a patient or a control, ND or LD. 
The reader classified each image as normal or 
pathological, giving a confidence score of 0-5 
(discriminative confidence). If the image was 
classified as pathological, an extra assessment 
was made regarding the specific diagnosis (AD/
FTD/LBD/CBD).
In the quantitative part of the study, the Z- 
score differences of all neocortical regions 
were tested for normal distribution using 
Shapiro-Wilks test and visualized with normal 
probability plots for detection of outliers. Single 
sample t-tests were used to determine if there 
was constant bias between the normal and 
low-dose Z-scores, and simple regression was 
used to quantify proportional bias, expressed 
as an R2 and a p value. 
In the qualitative session one, Cohen’s kappa 
test was used for inter-reader agreement, and 
to describe the contingency tables, in conjunc-
tion to Pearson chi-square. Wilcoxon matched 
pairs test was used to compare the confidence 
scores. A proportion test was used for the rate 
of correct diagnosis. In session two, Wilcoxon 
matched pairs and mean values with confi-
dence intervals were used to determine if there 
was any significant preference for ND- or 
LD-derived images. Graphs and most statisti-
Figure 2. Z-scores from normal-versus low-dose. The plot shows an excerpt 
of the clinically most relevant Z-score range. Each data point shows one 
neocortical region in one subject; with the normal-dose derived Z-score on 
the X-axis and the low-dose derived Z-score on the Y-axis. Using -1.96 as a 
general cut-off between normal and pathological, the yellow fields contain 
41 data points that would be misclassified by low-dose derived Z-scores, 
compared to normal-dose.
Session two
The second session was car-
ried out on a separate occa-
sion. The readers viewed two 
sets of Z-maps at a time; 
the ND and LD images from 
each subject. In half of the 
cases (randomly decided), the 
ND images were above the 
LD images and vice versa. 
Selected projections from all 
included patients are shown 
in Figure 1. The clinical diag-
nosis of the subject (Control/
AD/FTD/LBD/CBD) was given 
next to the images. For each 
subject, the readers decided 
which set of images was most 
consistent with the clinical 
diagnosis, together with a sub-
jective quantification of how 
large the difference between 
the images were, on a scale 
from 0-5. Note that a differ-
ence of zero, meaning that the 
images had identical consist-
ency with the diagnosis, was a 
valid option for the readers as 
some pairs of images were 
identical or near identical.
Statistical methods
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cal calculations were made using Dell Statistica, 
version 13. Kappa values were calculated with 
IBM SPSS Statistics version 23.
col compared to ND (e.g. LD showing -2.34 
while ND showed -2.54), whereas no such bias 
was found for positive Z-scores. 
Figure 3. Bland-Altman analysis for neocortical regions, comparing normal- 
and low-dose. There is a significant constant bias in combination with a 
slight negative proportional bias, which in combination represents an un-
derestimation of negative Z-scores by the low-dose protocol, compared to 
normal-dose.
Table 2. Shows the results from the diagnostic assessment in 
qualitative session 1
Normal-dose Low-dose
Image rated as Controls Patients Controls Patients
Normal 15 5 15 5
Pathological 3 13 3 13
Of which uncertain 1 1 0 2
Sensitivity 72% 72%
Specificity 83% 83%
Negative pred v 75% 75%
Positive pred v 81% 81%
Accuracy 78% 78%
Correct ddx 67% 56%
n: 36 n: 36
K: 0.556 K: 0.556
p: 0.0008 p: 0.0008
Assessments from both readers are added (n=18 × 2). “Pred v” 
represents predictive value. The assessments were not identical between 
normal- and low-dose derived images, but the numbers of assessments in 
each category were, thus resulting in identical discriminative performance 
between the methods. “Uncertain” represents assessments with a 
discriminative confidence score < 3. “Correct ddx” refers to the rate of 
correct diagnoses among the true positive cases. K represents kappa 
values for the contingency tables, not to be confused with interreader 
agreement.
Results
Selected projections from all 
included patients are provid-
ed in Figure 1. The readers 
were presented with surface 
projections in all planes but 
representative images were 
chosen for this figure. 
Quantitative assessment
The difference between the 
ND- and LD-derived Z-scores 
were evaluated in several as- 
pects as described in the 
following sections. Initially, Z- 
score differences were com-
pared according to the size 
and signal intensity per voxel 
in each region of interest, to 
test for bias from regional 
size. There was no such sig-
nificant correlation. A cropped 
scatter plot of the clinically 
relevant range of Z-scores is 
shown in Figure 2. Considering 
-1.96 as a general cut-off limit 
to separate normal from path-
ological values, 41 out of 648 
(6.33%) data points would be 
misclassified (false negative, 
false positive) by the LD proto-
col compared to ND, as high-
lighted by the yellow fields 
in the figure. The differences 
were normally distributed and 
no outliers were identified.
Bland-Altman comparisons 
between the doses showed a 
significant constant bias of 
0.206 (P < 0.001), as shown 
in Figure 3. There was also a 
minimal, but significant, nega-
tive proportional bias (R2= 
0.014, P=0.002). The combi-
nation of a constant positive 
bias and a negative propor-
tional bias signifies that nega-
tive Z-scores were reported as 
less negative by the LD proto-
Z-score maps from low-dose FDG-PET
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This finding was confirmed by dividing the data 
points to two groups; negative and positive 
ND-derived Z-scores. The first group had a 
t-test confirmed significant constant bias, but 
no bias was found in the second group.
Qualitative assessment 
Session one: The results for discrimination 
between patients and healthy controls are 
shown in Table 2. The sum of assessments in 
each category was identical, resulting in equal 
discriminative performance between doses. 
The LD images had slightly higher mean dis-
criminative confidence score (4.22 versus 4.11 
for ND); the ND and LD images were preferred 
in 11 instances each, thus showing no signifi-
cant difference. The rate of uncertain cases 
(discriminative confidence score < 3) was 6% in 
both dose groups. Kappa values for inter-read-
er agreement were 0.778 for normal-dose and 
0.571 for low-dose. Regarding differential diag-
noses, correct diagnoses were given in 67% of 
normal-dose assessments, and in 56% of low-
dose assessments; a non-significant difference 
at P=0.49. 
Session two: When comparing which set of 
images was most consistent with the clinical 
diagnosis, the ND images were preferred in 8% 
of the assessments, the LD images in 13%, and 
they were deemed equal in 79%. The difference 
was not significant. The data was also translat-
ed to a semi-continuous scale of 11 steps, 
where “-5” represented strongest difference in 
favour of LD, “0” represented no difference, 
and “5” strongest difference in favour of ND. 
The mean of the assessments on this scale 
was -0.05, and the 95% confidence interval 
included zero.
Discussion
The main finding of this study was that visual 
assessment of 3D-SSP Z-score maps from low-
dose FDG-PET provided highly similar diagnos-
tic information, although the quantitative val-
ues had some degree of discrepancy compared 
to normal-dose. The high level of similarity 
between doses can be of clinical and scientific 
relevance from a dose-reduction point of view. 
The findings include a slight understating of 
negative Z-score values from the LD protocol, 
and a stronger inter-reader agreement for ND. 
Regarding differential diagnosis, there was a 
trend in favour of ND, but no significant differ-
ence, and the discrimination between patients 
and healthy controls were identical between 
doses. The results from this study in conjunc-
tion with the preceding SUV ratio analysis [11] 
strongly suggest the feasibility of a substantial 
FDG-dose reduction in clinical routine.
A normal-dose scan with shorter acquisition 
time approximates a low-dose scan, but there 
are differences in count rates that adversely 
affect image quality. Validation using a true 
low-dose protocol was deemed necessary for 
clinical implementation, ensuring a valid com-
parison. In particular, random count rates are 
proportional to the square of the amount of 
radioactivity present in the field of view of 
the scanner, whereas true count rates show a 
near-linear proportionality at the relatively low 
activity concentrations encountered during a 
clinical brain FDG scan. Thus, a scan with a 
reduced dose will have a higher signal-to-noise 
ratio than a scan with a reduced acquisition 
time. As shown in Figure 1, the visual similari-
ties between a routine scan and LD were 
substantial.
In the search for methods to track disease 
progression rate in clinical trials, many studies 
have explored the rate of atrophy and the rate 
of ventricular dilatation, as summarized by 
Frisoni et al. [13]. Yearly reduction of hippo- 
campal volume has been found to be larger in 
patients than age-matched controls. Repeated 
low-dose FDG-PET examinations might provide 
a similar quantitative “rate-of-progression” 
measurement for cortical metabolism, which 
could be useful in identifying pathology at early 
stages of disease and monitoring disease pro-
gression rate [14]. Using 3D-SSP maps to cal-
culate and visualize the rate of progression is 
likely a robust and appealing approach. 
The main limitation of this study is the group 
sizes. It is theoretically possible that the trend 
towards superior differential diagnostic capa-
bility with ND would have been significant with 
a larger sample, but visual comparisons of 
the current material does not support that the-
ory. A second important limitation was the lack 
of normal-dose reproducibility data based on 
modern reconstruction algorithms. A separate 
group of Z-scores using normal-dose FDG-PET/
CT twice would provide a reliability measure 
that might allow stronger interpretations of the 
Z-score maps from low-dose FDG-PET
245 Am J Nucl Med Mol Imaging 2018;8(4):239-246
current results. Pairwise comparisons have 
been shown to be more reliable than subjective 
grading alone [15], which motivated the second 
reading session in this study.
It is possible that a scanner with higher sensi-
tivity and higher signal-to-noise ratio would pro-
vide slightly different quantitative results, but 
qualitative assessment would probably remain 
similar. The data presented in the current work 
were acquired using a previous generation 
PET-CT scanner based on BGO detectors and 
photomultiplier tubes, with considerably inferi-
or image quality than the latest generation of 
higher-sensitivity, time-of-flight-capable scan-
ners that are equipped with LSO or LYSO detec-
tors and silicon photomultiplier. This, combined 
with further improvements in image reconstruc-
tion algorithms, further strengthens the case 
for low-dose FDG brain PET.
Conclusion
3D-SSP Z-score maps created from low-dose 
FDG-PET scans of the brain, using 0.75 MBq/
kg, are highly similar to Z-score maps from nor-
mal-dose scans.
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